ArticleDiscover oncology2025
miR-146a-5p suppresses migration and downregulates vimentin and MMP-9 expression in gastric cancer cells.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ZIF-8/polydopamine nanocomposite functionalized with hyaluronic acid and folic acid for pH-responsive resveratrol delivery and apoptosis induction in colorectal cancer.Scientific reports · 2026Article
- Phosphorylated-EGFR and MMP7 upregulation in gastric cancer: Association with metastasis and poor prognosis.Oncology letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is a significant global health issue, characterized by poor prognosis due to its metastatic nature. This study investigates the role of microRNA-146a-5p (miR-146a-5p) in regulating migration and invasion of KATO III GC cells by targeting vimentin and matrix metalloproteinase-9 (MMP-9), critical mediators of epithelial-mesenchymal transition (EMT). miR-146a-5p expression was analyzed in GC cell lines, and functional assays were performed after transfection with a miR-146a-5p mimic. Results showed that miR-146a-5p expression was significantly reduced in GC cells, particularly in KATO III. Transfection with the mimic reduced cell viability, increased apoptosis, and inhibited migration, as shown by wound-healing assays. Additionally, miR-146a-5p downregulated vimentin and MMP-9 mRNA expression. These findings suggest that miR-146a-5p may influence metastatic behavior in GC cells through regulation of EMT-related genes. However, further studies, including protein-level validation and direct target confirmation, are needed. These results provide a basis for future investigation into the potential therapeutic role of miR-146a-5p in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.